clinical trial · NCT02135705
LOWER: Lomitapide Observational Worldwide Evaluation Registry
Amryt Pharma·—·recruiting·n = 300
Homozygous Familial HypercholesterolemiaLomitapide
brief summary
This global product exposure registry is a multicentre, long-term, prospective, observational cohort study (exposure registry), designed to evaluate the long term safety and effectiveness of lomitapide.
started
Mar 18, 2014
primary completion
Mar 1, 2028
completion
Sep 1, 2028
last updated
Mar 12, 2024
detailed description
To evaluate the occurrence of adverse events of special interest, long term effectiveness of lomitapide, and to evaluate whether prescribers of lomitapide are following screening and monitoring recommendations as specified in product labeling.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol